Breaking News, Collaborations & Alliances

Adimab in Licensing Pacts with Biogen, GSK

Covers antibody discovery platforms

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Adimab, LLC has expanded its collaboration with Biogen Idec for the discovery of antibody-based therapeutics. Adimab will license and transfer its antibody discovery platform to Biogen for the discovery and optimization of all antibody formats, including bispecific antibodies. Adimab has also entered a technology transfer and license agreement with GlaxoSmithKline.   BI will receive a custom human antibody library that is exclusive to Biogen and will obtain a license to the Adimab Platform for u...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters